Navigation Links
AstraZeneca Implements Customized Cytel East(R) Software for More Accurate Trial Monitoring and Clinical Data Analysis
Date:2/13/2009

Top Global Pharmaceutical Company Integrates Their Clinical Data System (CDS) and East(R) for Improved Clinical Data Handling and Trial Analysis

CAMBRIDGE, Mass., Feb. 13 /PRNewswire/ -- Cytel Inc. today announced that AstraZeneca International has expanded their deployment of Cytel's East(R) software, the most widely-used clinical trial design, simulation and monitoring system available. AstraZeneca's increased use of East(R) also features automated data transfer between their CDS and East's trial monitoring component. By eliminating manual data entry, AstraZeneca achieved the multiple benefits of greater clinical trial analysis efficiency and increased security of vital study data.

Cytel Vice President of Business Development, Steve Herbert, recalled the initial request: "AstraZeneca came to Cytel looking to improve data entry into East(R) from their own Clinical Data System (CDS). Our software engineers worked closely with their AstraZeneca's counterparts to help achieve far more efficient data handling within their CDS path and ensure compliance with Clinical Data Interchange Standards Consortium (CDISC) guidelines."

Maria Johansson, Business Tools Manager at AstraZeneca praised Cytel's response saying, "Cytel's customized version of East(R) for AstraZeneca is now fully integrated with our clinical data system eliminating any manual data handling and better facilitating the data analysis process. This new automation also helps us maintain the integrity of the interim data, reducing the risk of unintentional un-blinding."

Of the experience, Mrs. Johansson remarked, "The cooperation between AstraZeneca and Cytel has been very good. We're very pleased with the outcome."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

About Cytel

Cytel Inc. is a leading provider of clinical trial design services and specialized statistical software for the biopharmaceutical, medical device, academic, and government research markets. Cytel's East(R) system is used at hundreds of commercial sites, throughout academia and by regulators to design, simulate and monitor adaptive and group sequential clinical trials. Cytel provides trial sponsors with innovative tools, training and consultation to increase the return on investment in clinical development.


'/>"/>
SOURCE Cytel Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America
2. AstraZeneca Nobel Medicine Initiative to Increase Interest in the Nobel Prize in Physiology or Medicine
3. AstraZeneca and M. D. Anderson Renew Cancer Research Collaboration
4. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
5. Melior Enters Research Collaboration with AstraZeneca
6. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
7. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
8. Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca
9. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
10. WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca
11. AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... 3, 2016  With the growing need for ... is underway, therapies such as monoclonal antibodies, recombinant ... host of indications are in high demand. Conventionally ... development and production of these therapeutics. However, due ... high costs, novel approaches and novel expression systems ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier of ... North American healthcare market. , Aerocom Healthcare, LLC will be based in Denver, ... provide new pneumatic tube systems or expand existing systems within the U.S. and ...
Breaking Biology Technology:
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , ... a developer of innovative sensor-based diagnostic products, today announced the ... by new and existing investors.  Proceeds from the financing will ... Scanner , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The ...
Breaking Biology News(10 mins):